Evidence map›Paper›PMID 26690291›Full record

Trial reportJournal of addiction medicine

Presence or Absence of QTc Prolongation in Buprenorphine-Naloxone Among Youth With Opioid Dependence.

Sabrina A Poole, Anna Pecoraro, Geetha Subramaniam, George Woody, Victoria L Vetter

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Effects of opioid receptor agonist and antagonist medications on electrocardiogram changes and presentation of cardiac arrhythmia: review article.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2022
    Review
  6. Review
  7. Pain medication and long QT syndrome.The Korean journal of pain · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sabrina A PoolePerelman School of Medicine at the University of Pennsylvania (SAP, AP, GW); The Children's Hospital of Philadelphia, Philadelphia, PA (VLV); Deputy Director, The Center for Clinical Trials Network, National Institute on Drug Abuse (G.S.).
Anna Pecoraro
Geetha Subramaniam
George Woody
Victoria L Vetter
Verein zur Förderung Innovativer Verfahren in der Logistik · DE

Funding

Delaware Valley Node of the Clinical Trials NetworkU10DA013043 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI WOODY, GEORGE EDWARD · 1999 to 2015
$25.8M
Treatment/Substance Use Disorders/HIV Risk ReductionK05DA017009 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI WOODY, GEORGE EDWARD · 2003 to 2012
$1.3M
NIDA NIH HHS 2K05 DA01700906NIDA NIH HHS 5U10 DA1304308NIDA NIH HHS K05 DA017009NIDA NIH HHS U10 DA013043
6 · The paper itself

Abstract

objectivesThe aim of the study was to evaluate buprenorphine-naloxone effects on the QTc in youth with opioid dependence. Buprenorphine is a partial agonist that is an effective treatment for opioid dependence. Compared with methadone, it has a lower risk of QTc prolongation in adults, but is less studied in the youth. It may also reduce the risk of torsades de pointes (TdP)--an uncommon variant of polymorphic ventricular tachycardia--that can result in syncope, ventricular fibrillation, and sudden death.

methodsSecondary analysis of the electrocardiogram data from 95 individuals who participated in a multisite trial for youth with opioid dependence. The participants were randomized to a 2-week (DETOX) or a 12-week course of buprenorphine-naloxone (BUP). At baseline, 12-lead electrocardiograms were done at weeks 4 and 12, and QTc intervals were hand-measured and calculated using Bazett formula. Increases above 60 milliseconds were considered clinically significant, and readings above 450 milliseconds (in men) and 470 milliseconds (in women) indicated a prolonged QTc.

resultsMean QTc intervals were higher for BUP than for DETOX participants at baseline, week 4, and week 12 (P = 0.045), and women had longer mean QTc intervals than men (P < 0.0005). Variations in the QTc intervals were observed in some; however, none were above 500 milliseconds--the level at which risk for TdP becomes more significant.

conclusionsIn this randomized trial, the mean QTc at baseline, before randomization, was higher in BUP than in DETOX patients. Minimal changes in the QTc were seen at 4 and 12 weeks in a few patients in both groups. There was no evidence that buprenorphine-naloxone alone increased the QTc to a level that increased the risk for TdP.

Indexed as

AdolescentAdultBuprenorphine, Naloxone Drug CombinationElectrocardiographyFemaleHumansLong QT SyndromeMaleOpioid-Related DisordersYoung AdultBuprenorphine, Naloxone Drug Combination

Identifiers

PMID26690291
PMCPMC4733605
OpenAlexW2331816100

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.